Susceptibility patterns and characterization of beta-lactamases in clinical isolates ofBacteroids fragilis

  • P. Mastrantonio
  • P. Spigaglia
  • A. Sebastianelli
Article

Abstract

Strains ofBacteroides fragilis isolated from clinical specimens are known to be frequently resistant to penicillins or cephalosporins. The production of beta-lactamases is the major mechanism in this resistance. Up to now at least five types of beta-lactamase enzymes have been described in theBacteroides fragilis group. The purpose of this study was to evaluate the susceptibility to different antibiotics and the prevalence of the beta-lactamase types among 100Bacteroides fragilis strains isolated from clinical specimens in Italy. MICs of 11 antibiotics were determined by the reference agar dilution method and by the new E test (AB Biodisk, Sweden). Results showed an acceptable correlation between the MICs determined for most strains, although those obtained by the E test tended to be lower. In the beta-lactam resistant strains the enzyme activity and isoelectric points were determined on crude enzyme extract.

Keywords

Agar Penicillin Cephalosporin Clinical Isolate Isoelectric Point 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Finegold SM: Anaerobic bacteria in human disease. Academic Press, New York, 1977, p. 68–77.Google Scholar
  2. 2.
    Phillips I, King A, Nord CE, Hoffstedt B: Antibiotic sensitivity of theBacteroides fragilis group in Europe. European Journal of Clinical Microbiology and Infectious Diseases 1992, 11: 292–304.CrossRefGoogle Scholar
  3. 3.
    Fox AR, Phillips I: The antibiotic sensitivity of theBacteroides fragilis group in the United Kingdom. Journal of Antimicrobial Chemotherapy 1987, 20: 477–488.PubMedGoogle Scholar
  4. 4.
    Dubreuil L, Derriennic M, Sedallian A, Romond C, Courtieu AL: Evolution in antibiotic susceptibility ofBacteroides fragilis group strains in France based on periodic surveys. Infection 1989, 17: 197–200.CrossRefPubMedGoogle Scholar
  5. 5.
    Nord CE: Mechanism of beta-lactam resistance in anaerobic bacteria. Reviews of Infectious Disease 1986, 8, Supplement 5: 543–548.Google Scholar
  6. 6.
    Tally FP, Cuchural GJ Jr: Antibiotic resistance in anaerobic bacteria. Journal of Antimicrobial Chemotherapy 1988, 22: 63–71.Google Scholar
  7. 7.
    Sato K, Matsuura Y, Inoue M, Mitsuhashi S: Properties of a new penicillinase type produced byBacteroides fragilis. Antimicrobial Agents and Chemotherapy 1982, 22: 579–584.PubMedGoogle Scholar
  8. 8.
    Cuchural GJ Jr, Malamy MH, Tally FP: Beta-lactamase-mediated imipenem resistance inBacteroides fragilis. Antimicrobial Agents and Chemotherapy 1986, 30: 645–648.PubMedGoogle Scholar
  9. 9.
    Cuchural GJ Jr, Tally FP, Jacobus NV, Marsh PK, Mayhew JW: Cefoxitin inactivation byBacteroides fragilis. Antimicrobial Agents and Chemotherapy 1983, 24: 936–940.PubMedGoogle Scholar
  10. 10.
    Sanchez ML, Jones RN: E-test, an antimicrobial susceptibility testing method with broad clinical and epidemiological application. Antimicrobic Newsletter 1993, 8: 1–8.CrossRefGoogle Scholar
  11. 11.
    Sutter VL: Susceptibility testing of anaerobes. In: Lennett EH, Balows A, Hausler WJ (ed): Manual of clinical microbiology. American Society for Microbiology, Washington DC, 1985, p. 988–990.Google Scholar
  12. 12.
    Rodloff AC, Appelbaum PC, Zabransky RJ: Cumitech 5A. In: Rodloff AC (ed): Practical anaerobic bacteriology. American Society for Microbiology, Washington DC, 1991.Google Scholar
  13. 13.
    Citron DM, Ostovari MI, Karlsson A, Goldstein EJC: Evaluation of the E test for susceptibility testing of anaerobic bacteria. Journal of Clinical Microbiology 1991, 29: 2197–2203.PubMedGoogle Scholar
  14. 14.
    Edwards R, Greenwood D: An investigation of beta-lactamases from clinical isolates ofBacteroides species. Journal Medical Microbiology 1992, 36: 89–95.Google Scholar
  15. 15.
    Edwards R, Greenwood D: Effect of growth conditions and storage on the specific activity of beta-lactamases ofBacteroides species. Journal of Applied Bacteriology 1990, 69: 421–425.PubMedGoogle Scholar
  16. 16.
    Schindler P, Huber G: Use of PADAC, a novel chromogenic beta-lactamase substrate for the detection of beta-lactamase producing organisms and assays of beta-lactamase inhibitors/inactivators. In: Brodbeck U (ed): Enzyme inhibitors. Verlag Chemie, Weinheim, Germany, 1990, p. 169–176.Google Scholar
  17. 17.
    Matthew M, Harris AM, Marshall MJ, Ross GW: The use of analytical isolectric focusing for detection and identification of beta-lactamases. Journal of General Microbiology 1975, 88: 169–178.PubMedGoogle Scholar
  18. 18.
    Waley SG: A spectrophotometric assay of beta-lactamase action on penicillins. Journal of Biochemistry 1974, 139: 789–790.Google Scholar
  19. 19.
    O'Callaghan CH, Morris A: Inhibition of beta-lactamases by beta-lactam antibiotics. Antimicrobial Agents and Chemotherapy 1972, 2: 442–448.PubMedGoogle Scholar
  20. 20.
    Betriu C, Campos E, Cabronero C, Rodriguez-Avial C, Picazo JJ: Susceptibilities of species of theBacteroides fragilis group to 10 antimicrobial agents. Antimicrobial Agents and Chemotherapy 1990, 34: 671–673.PubMedGoogle Scholar
  21. 21.
    Bourgault AM, Lamothe F, Honab DJ, Dalton MT, Kibsey PC, Harding G, Smith JA, Low DE, Gilbert H: Survey ofBacteroides fragilis group susceptibility patterns in Canada. Antimicrobial Agents and Chemotherapy 1992, 36: 343–347.PubMedGoogle Scholar
  22. 22.
    Murray PR, Niles AC: Comparison of the E-test (PDM Epsilometer) and broth microdilution susceptibility tests of theBacteroides fragilis group. Diagnostic Microbiology and Infectious Diseases 1991, 14: 501–505.CrossRefGoogle Scholar
  23. 23.
    Simpson IN, Plested SJ: The origin and properties of beta-lactamase satellite bands seen in isolelectric focusing. Journal of Antimicrobial Chemotherapy 1983, 12: 127–131.PubMedGoogle Scholar
  24. 24.
    Bush K: Characterization of beta-lactamases. Antimicrobial Agents and Chemotherapy 1989, 33: 259–263.PubMedGoogle Scholar
  25. 25.
    Maskell JP, Nasu M, Williams JD: Cephalosporin resistance in theBacteroides fragilis group and the effect of clavulanic acid. Journal of Antimicrobial Chemotherapy 1984, 13: 23–30.Google Scholar
  26. 26.
    Tally FP, O'Keefe JP, Sullivan NM, Gorbach SL: Inactivation of cephalosporins byBacteroides. Antimicrobial Agents and Chemotherapy 1979, 16: 565–571.PubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1994

Authors and Affiliations

  • P. Mastrantonio
    • 1
  • P. Spigaglia
    • 1
  • A. Sebastianelli
    • 1
  1. 1.Bacteriology and Medical Mycology DepartmentNational Institute of HealthRomeItaly

Personalised recommendations